NCT05098210: Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer |
|
|
| Recruiting | 1 | 20 | US | Neoantigen Peptide Vaccine, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid | Fred Hutchinson Cancer Center, Amazon.com Services LLC | Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Locally Advanced Cutaneous Melanoma, Metastatic Acral Lentiginous Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Acral Lentiginous Melanoma, Recurrent Cutaneous Melanoma, Recurrent Mucosal Melanoma, Refractory HER2-Negative Breast Carcinoma, Unresectable Acral Lentiginous Melanoma, Unresectable Cutaneous Melanoma, Unresectable Mucosal Melanoma | 11/24 | 11/25 | | |
